| Literature DB >> 22244938 |
X Christopher Sheng1, Anthony Casarez, Ruby Cai, Michael O Clarke, Xiaowu Chen, Aesop Cho, William E Delaney, Edward Doerffler, Mingzhe Ji, Michael Mertzman, Rowchanak Pakdaman, Hyung-Jung Pyun, Tanisha Rowe, Qiaoyin Wu, Jie Xu, Choung U Kim.
Abstract
A potent and novel class of phosphinic acid derived product-like inhibitors of the HCV NS3/4A protease was discovered previously. Modification of the phosphinic acid and quinoline heterocycle led to GS-9256 with potent cell-based activity and favorable pharmacokinetic parameters. Based on these attributes, GS-9256 was advanced to human clinical trial as a treatment for chronic infection with genotype 1 HCV.Entities:
Mesh：
Substances：
Year: 2011 PMID： 22244938 DOI： 10.1016/j.bmcl.2011.12.038
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823